NeoImmuneTech announces clinical results for pancreatic cancer and colon cancer for the first time at ASCO

input2024.04.25 09:21
correction2024.04.25 09:21

First public release of clinical results for 50 people

NeoImmuneTech, an immunotherapy development company, will reveal the clinical results of its candidate drug ‘NT-I7’ (epineptakine alfa) at the American Society of Clinical Oncology (ASCO) held in Chicago, USA next month.

NeoImmuneTech announced on the 25th that it plans to present three posters on the combination clinical and non-clinical results of its candidate material, NT-I7, at ASCO. ASCO will be held from May 31 to June 4 in Chicago, USA.

NT-I7 is a long-acting immuno-anticancer drug candidate that improves the cytokine ‘Interleukin 7’ (IL-7), which increases the number and glides of T cells, which are immune cells.

In this poster presentation, NeoImmuneTech announced for the first time the results of combined administration of NT-I7 and the immunotherapy drug ‘Keytruda’ (pembrolizumab) to a total of 48 patients with pancreatic cancer and 50 patients with microsatellite stable (MSS) colorectal cancer. do. Additionally, NeoImmuneTech plans to announce the results of a biomarker analysis of the results of combined administration of NT-I7 and Keytruda in patients with pancreatic cancer and MSS colon cancer.

NeoImmuneTech is conducting clinical trials by recruiting 24 and 25 additional patients for pancreatic cancer and MSS colon cancer, respectively, through follow-up discussions with Merck (MSD) of the United States for the development of Keytruda.

In addition, we present the results of administering an anticancer vaccine using the Zika virus in combination with NT-I7 in a glioblastoma animal model. This is additional data following the results of the strong anticancer effect of anticancer vaccine and NT-I7 announced by the Society of Neuro-Oncology (SNO) last year.

Oh Yoon-seok, CEO of NeoImmuneTech, said, “We have confirmed that the lives of patients with pancreatic cancer and MSS colon cancer have improved through the T-cell amplification efficacy of NT-I7.” He added, “Based on the data on the T-cell amplification efficacy of NT-I7 confirmed so far, “We are working on ways to get NT-I7 approved,” he said.

Reporter Lee Woo-sang [email protected]